Inventor · disambiguated record
Marie-Odile Roy
Also filed as: ROY MARIE-ODILE
10 granted patents·1 pending application·25 citations·filing 2007–2020
84Inventor score
Top patents by PatentIndex Score
11 records- 0191US8871761B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersEUROSCREEN SA·Filed 2012·Granted Oct 28, 2014·15 cites·12 claims
- 0283US9475814B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofEUROSCREEN SA·Filed 2012·Granted Oct 25, 2016·7 cites·20 claims
- 0377US10065961B2Chiral N-acyl-5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofEUROSCREEN SA·Filed 2016·Granted Sep 4, 2018·2 cites·5 claims
- 0474US10683295B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-A]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofOGEDA SA·Filed 2018·Granted Jun 16, 2020·1 cites·5 claims
- 0567US10941151B2Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereofOGEDA SA·Filed 2020·Granted Mar 9, 2021·0 cites·4 claims
- 0664US2020125564A1Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disordersOGEDA SA·Filed 2019·Application pending·0 cites
- 0761US9926325B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2014·Granted Mar 27, 2018·0 cites·4 claims
- 0859US10544150B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2018·Granted Jan 28, 2020·0 cites·12 claims
- 0942US7824866B2Ligand for G-protein coupled receptor GPR72 and uses thereofEUROSCREEN SA·Filed 2007·Granted Nov 2, 2010·0 cites·19 claims
- 1040US8497075B2Methods of identifying a modulator that inhibits the binding between Epstein-Barr virus induced receptor 2 and cholesterol derived ligandsBAUMGARTEN BIRGIT·Filed 2009·Granted Jul 30, 2013·0 cites·8 claims
- 1136US10065960B2NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disordersOGEDA SA·Filed 2015·Granted Sep 4, 2018·0 cites·12 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →